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Abstract: Salivary IL-6 mRNA was previously identified as a promising biomarker of oral
squamous cell carcinoma (OSCC). We performed a multi-center investigation covering all geographic
areas of Hungary. Saliva from 95 patients with OSCC and 80 controls, all Caucasian, were
collected together with demographic and clinicopathological data. Salivary IL-6 mRNA was
quantified by real-time quantitative PCR. Salivary IL-6 protein concentration was measured by
enzyme-linked immune-sorbent assay. IL-6 protein expression in tumor samples was investigated by
immunohistochemistry. Normalized salivary IL-6 mRNA expression values were significantly higher
(p < 0.001) in patients with OSCC (mean ± SE: 3.301 ± 0.885) vs. controls (mean ± SE: 0.037 ± 0.012).
Differences remained significant regardless of tumor stage and grade. AUC of the ROC curve was
0.9379 (p < 0.001; 95% confidence interval: 0.8973–0.9795; sensitivity: 0.945; specificity: 0.819). Salivary
IL-6 protein levels were significantly higher (p < 0.001) in patients (mean ± SE: 70.98 ± 14.06 pg/mL),
than in controls (mean± SE: 12.45± 3.29). Specificity and sensitivity of IL-6 protein were less favorable
than that of IL-6 mRNA. Salivary IL-6 mRNA expression was significantly associated with age and
dental status. IL-6 manifestation was detected in tumor cells and tumor-infiltrating leukocytes,
suggesting the presence of a paracrine loop of stimulation. Salivary IL-6 mRNA is one of the best
performing and clinically relevant biomarkers of OSCC.
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1. Introduction
Hungarian males and females exhibit the highest age-standardized rates both for the incidence
and the mortality of oral cavity and pharyngeal cancers in Europe without substantial improvements in
the last decades [1]. Frequently, oral squamous cell carcinoma (OSCC) is being diagnosed in advanced
stages, i.e., stage III and IV, with long-term survival rates around 50% despite considerable progress in
surgical methods, radio-, chemo-, and immunotherapy. In contrast, patients with early, i.e., stage I and
II lesions, may experience recovery rates up to 80%. Unfortunately, with the exception of the gold
standard procedure, tissue biopsy and histopathological analysis, there are no evidence-based, reliable,
non-invasive methods for large-scale screening and early detection of OSCC [2,3].
The aim of the present investigation was to study the potential of salivary IL-6 mRNA and
IL-6 protein as OSCC-related biomarkers. Saliva was chosen as a complex, informative body-fluid
containing biomolecules that originate from multiple sources and may differentiate between healthy
subjects and patients with OSCC. Application of advanced molecular methods resulted in the discovery
of several candidate salivary proteins, metabolites, mRNAs, miRNAs, and circRNAs associated with
OSCC. However, there has been a high degree of variation between results reported by different
investigators with respect to the value of these biomolecules as biomarkers detected in patients of
different geographic and ethnic backgrounds [4–10]. In addition, salivary levels of inflammatory
cytokines, considered as one of the best performing molecular groups of OSCC biomarkers, may be
confounded by the presence of oral inflammatory lesions [11–13].
Previously, we applied both targeted and high-throughput molecular methods to identify
potentially useful mRNA and protein biomarkers in a small-scale single-institution pilot cohort
of patients with OSCC and controls [12,13]. These pilot transcriptomic and proteomic investigations
suggested that salivary IL-6 mRNA and protein may prove the best performing biomarkers of OSCC
in the Hungarian population. Therefore, we investigated salivary IL-6 mRNA and IL-6 protein
in a sample of patients with OSCC covering each geographic area of Hungary. To support the
relevance of salivary IL-6 mRNA expression, we were looking for differences in salivary IL-6 protein
concentrations of patients and controls and by detecting the expression of IL-6 protein in tumor cells
and in tumor-infiltrating leukocytes (TIL). An additional objective was to analyze associations of
salivary IL-6 mRNA and protein expression with age, sex, gingival inflammation status, smoking, and
ethanol consumption habits in patients with OSCC.
2. Materials and Methods
2.1. Patients and Control Subjects
Between 2 May 2013 and 31 December 2015, 95 adult (>18 years) patients with OSCC, presenting a
suitable saliva sample, were enrolled in a multi-centric investigation from four Hungarian sites: Faculty of
Dentistry, University of Debrecen, Debrecen (“Debrecen Center”): 26 patients; Faculty of Dentistry, Scientific
University of Szeged, Szeged (“Szeged Center”): 24 patients; Faculty of Dentistry, Scientific University
of Pécs, Pécs (“Pécs Center”): 25 patients; and Faculty of Dentistry, Semmelweis University, Budapest
(“Budapest Center”): 20 patients. Eighty age-matched adult controls, admitted for dental check-ups, were
recruited from the same sites. Subjects with previous and present cancer, except for the present OSCC
(patients), coexisting diabetes, autoimmune disorders, contagious diseases, and pregnancy were excluded.
The investigation was approved by the Institutional Review Board of the University of Debrecen
(No. 3244–8/2011, No. 3722–2012) and by the Scientific and Research Ethics Committee, Medical
Research Council, Hungary [(693/PI/12.) 45038-1/2012/EKU]. The Code of Ethics of the World Medical
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Association and the ethical standards of the 2000 Revision of the Helsinki Declaration were respected.
Signed informed consent was obtained from all participating subjects.
Examination of the oral cavity and the head and neck region was performed by a licensed
dental and/or maxillofacial surgeon according to standard methods and criteria of the World Health
Organization [14]. Tooth decay was characterized using the DMFT index by calculating the number
of decayed (D), missing (M), and filled (F) teeth (T). Periodontal health was characterized by the
gingival index (GI) [15]. Suspicious lesions were removed or biopsied, and OSCC was verified by
histology investigating the hematoxylin- and eosin-stained slides. The histological differentiation grade
of OSCC was defined according to the classification of the World Health Organization (WHO) [16].
The staging was performed according to the 8th edition of the TNM classification of the International
Union Against Cancer [17]. Demographic and clinicopathological data, including age, sex, stage,
and grade of OSCC, DMFT, and GI indices, were recorded. The stage and grade of OSCC lesions
were not available from study subjects of the Pécs Center. Smoking and ethanol consumption habits
were recorded from consenting subjects as precisely as possible. Based on the information obtained,
we formed two groups in each category. Regarding smoking habits, we distinguished regular smokers
and non-smokers/occasional smokers (<10 cigarettes/day). Regarding ethanol consumption habits,
we formed two categories: people who consumed ethanol-containing beverages at least once a week
vs. those who drank less than once a week.
2.2. Saliva Collection and Processing
Unstimulated saliva samples were collected between 9:00 and 11:00 a.m. Patients and controls
refrained from eating, drinking, smoking, gum chewing, and performing oral hygiene measures for at
least 60 min before sampling. A minimum of 5.0 mL saliva was collected from each participant. Samples
were kept on ice throughout collection and processing. Samples were pushed five-times through
a 19 g needle then filtered (Millex 25 mm Durapore PVDF 5 µm Sterile, Merck KGaA, Darmstadt,
Germany). Three aliquots of 200 µL filtered saliva were mixed with 1 mL PAXgene® reagent in
cryotubes, for immediate stabilization of salivary RNA (PAXgene® Blood RNA Tubes, BD Biosciences,
Cat.No. 762165, BD Franklin Lakes, NJ, USA). Aliquots of 0.5 mL were pipetted from the remaining
saliva filtrate into cryotubes, for ELISA (Cryopure tube, SARSTEDT, Cat.No. 72.380, Nümbrecht,
Germany). The PAXgene®-stabilized and proteomic saliva samples were frozen within 60 min from
collection and stored at −70 ◦C until processing.
2.3. Reverse Transcription and Real-Time Quantitative PCR (qPCR)
Salivary RNA was isolated with the Direct-zol™RNA MiniPrep Plus Kit (Zymo research, Cat.No. R2072,
Irvine, CA, USA) according to the manufacturer’s instructions. RNA sample quality and concentration were
characterized by Nanodrop spectrophotometry and by the Agilent 2100 Bioanalyzer system. Expression of
IL-6 mRNA and two normalizing genes, GAPDH and ACTB, were quantified using qPCR with TaqMan®
assays on a QuantStudio™ 12K Flex Real Time PCR System (Applied Biosystem®, Thermo Fisher Scientific,
Waltham, MA, USA). Raw data analysis was performed using the ExpressionSuite Software v1.0.3 (Applied
Biosystem®). Samples with a high standard deviation of replicates, or with only one replicate giving a
signal in the qPCR assay were categorized as borderline, non-quantifiable-positive ones. Ct values of the
latter samples were set uniformly to 39 for the calculations and statistical analysis.
For qPCR efficiency correction, raw Ct values of cDNA serial dilutions (from HeLa total RNA) were
used to determine the slope of the assays, using the linear regression function of GraphPad Prism software
(GraphPad Software, Inc., CA, USA). PCR efficiency values were calculated, Ct values were corrected, and
data were normalized. qPCR efficiencies were as follows: IL-6 = 0.904, GAPDH = 0.814, ACTB = 1.03.
Cutoff Ct values (limit of quantitation; LOQ) for each TaqMan® assay were also determined in these
experiments. Detailed descriptions of RNA methods were provided as Supplementary data.
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2.4. Enzyme-Linked Immune-Sorbent Assay (ELISA)
IL-6 protein concentration in saliva samples of patients and controls was determined in duplicates
by the sandwich ELISA kit (Human ELISA Kit EK0410, Boster Biological Technology Co., Pleasanton,
CA, USA) according to the manufacturer’s instructions. Optical density was measured at 450 nm, and
concentrations were calculated based on the recorded 7-point calibration curve. LOQ for IL-t6 protein
concentration was 4.96 pg/mL.
2.5. Immunohistochemistry (IHC)
Sections obtained from 41 preexisting formalin-fixed and paraffin-embedded tissue blocks of
patients with proven OSCC from the Debrecen Center were microscopically reviewed by an independent
pathologist (BD). Since IHC labeling of preexisting tissue blocks did not interfere with salivary IL-6
mRNA and protein measurements, 15 samples from the previous pilot cohort were co-investigated
with the 26 samples collected in the course of the present investigation to increase sample size [12,13].
Serial sections were used for the detection of IL-6 manifestation in tumor cells and TILs by IHC, as
described in detail [18]. Briefly, mouse monoclonal antibodies (MoAb, clone 8H12; Invitrogen, Rockford,
IL, USA) to IL-6 (8H12; Invitrogen; Thermo Fisher Scientific, Rockford, IL, USA), CD3, CD4, CD20,
and CD163 (all from DAKO, Glostrup, Denmark) were used according to manufacturers’ instructions.
Peroxidase-conjugated anti-mouse secondary immunoglobulin was used with a peroxidase-based
detection kit (DAKO, Glostrup, Denmark) and VIP or DAB chromogenic substrates (Vector Labs,
Peterborough, UK) for visualization. Stained sections were digitalized using a Panoramic MIDI digital
slide scanner (3D-Histech-Zeiss, Budapest, Hungary) equipped with a Hitachi (HV-F22CL) 3CCD
camera. Image analysis was performed by the HistoQuant application of Panoramic viewer software
1.15.2 (3D-Histech, Budapest, Hungary) as described [19].
2.6. Statistical Analysis
Distribution of demographic characteristics and clinical parameters of patients and controls were
described by mean values and standard deviations (SD) for continuous variables. One-way ANOVA for
continuous and chi-square test for non-continuous variables were used to check for uneven distribution
of patients’ parameters between controls and cases. Statistical computation was carried out by IBM
SPSS Statistics version 20 (IBM SPSS Statistics for Windows, Version 20.0, Armonk, NY, USA).
In describing the expression of IL-6 mRNA and IL-6 protein, mean values and standard errors
(SE) were computed. Differences between patients and controls were assessed with GraphPad Prism,
using the Mann-Whitney U-test on the efficiency-corrected, normalized IL-6 mRNA expression values,
and IL-6 protein concentration values.
Receiver Operating Characteristic (ROC) curve analysis was carried out on the same data with
GraphPad Prism to evaluate the discrimination properties of IL-6 mRNA and IL-6 protein, and the
area under the curve (AUC) was determined.
Multivariate linear regression models were applied to investigate the influence of patients’ age, sex,
DMFT score, GI score, smoking, and ethanol consumption on IL-6 mRNA and IL-6 protein concentrations.
Before modeling, IL-6 mRNA and IL-6 protein concentrations were ln-transformed because of these
parameters showed right-tailed distribution. The normal distribution of ln transformed values was
checked by the Kolmogorov-Smirnov test. Results were described by linear regression coefficients with the
corresponding p-values. Statistical computation was carried out by IBM SPSS Statistics version 20.
3. Results
3.1. Characteristics of Study Participants
Demographic and clinicopathological characterization of 95 patients with newly diagnosed and
histologically-verified OSCC and 80 age-matched controls were summarized in Table 1. There were more
males (N = 60) than females (N = 35) among patients with OSCC, resulting in a significant difference
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in sex distribution between the patient and control groups. The patient group was characterized
by significantly higher DMFT scores than the group of controls. Smoking and ethanol consumption
were significantly more frequent among patients than controls. Both IL-6 mRNA and IL-6 protein
determination were successfully performed in 53 patient samples. Twenty-one and 21 samples, each,
from different patients were suitable for either IL-6 mRNA or IL-6 protein measurements. In the case
of the 80 controls, the number of successful salivary analyses were as follows, IL-6 mRNA and IL-6
protein: 55, IL-6 mRNA only: 9, and IL-6 protein: only 16 (Table S1: Demographic, clinicopathological
characterization, and IL-6 mRNA and IL-6 protein levels of individual patients with OSCC and controls).
Table 1. Demographic and clinicopathological characterization of patients with oral squamous cell
carcinoma (OSCC) and control subjects.
- Patients (N = 95) Controls (N = 80) P
Sex
Male 60 (63%) 30 (37%)
0.004 *Female 35 (37%) 50 (63%)
Age (years; mean ± SD) 61.7 ± 9.8 61.7 ± 9.2 0.982 **
OSCC stage
N = 70
St I 14 (20%) – na ***
St II 22 (31%) – na ***
St III 13 (19%) – na***
St IV 21 (30%) – na ***
Histological grade
N = 70
G1 17 (24%) – na ***
G2 42 (60%) – na ***
G3 11 (16%) – na ***
DMFT (N; mean ± SD) 64; 27.6 ± 6.4 47; 24.8 ± 6.9 0.011 **
GI (N; mean ± SD) 36; 0.53 ± 0.49 41; 0.42 ± 0.34 0.79 **
Ethanol
consumption
at least once a week 46 (48%) 14 (30%)
0.035 *less than once a week 49 (52%) 33 (70%)
Smoking regular smoking 62 (65%) 8 (17%) <0.001 *non-smoker or occasional smoker 33 (35%) 40 (83%)
N = number of patients * chi-square test; ** t-test; *** not applicable.
3.2. Salivary IL-6 mRNA and IL-6 Protein Expression
Saliva samples of 74/95 patients and 64/80 controls were suitable for qPCR. The majority of
saliva samples from patients were positive for IL-6 mRNA. Initially, there were 18 samples with no
quantifiable results. Reverse transcription and qPCR of these cases were repeated, resulting in 71
quantifiable results of 74 IL-6 mRNA samples from patients with OSCC. In contrast, 46 of 64 control
samples were non-quantifiable (36 negative, and 10 borderline positive samples) for IL-6 mRNA
expression, even in the repeated measurements. Normalized salivary IL-6 mRNA expression values
were significantly higher in the group of patients with OSCC than in controls. The difference remained
significant when subgroups of patients with different stages and grades were compared with controls
(Table 2, Figure 1A). There were no significant differences in IL-6 mRNA expression between subgroups
of patients with different stages and grades (data not shown). To test the sensitivity and specificity of
salivary IL-6 mRNA as a diagnostic biomarker for OSCC, an ROC curve analysis was performed, and
the AUC was calculated. The AUC for IL-6 mRNA was 0.9379 (p < 0.001; 95% confidence interval:
0.8973–0.9795; sensitivity: 0.945; specificity: 0.819) (Figure 1C).
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Table 2. Differential expression of IL6 mRNA and IL6 protein in the saliva of patients with OSCC
and controls.
IL-6 mRNA Normalized Values IL-6 Protein [pg/mL]
Sample N mean SE p * N mean SE p *
OSCC
St I-II 31 1.634 0.400 <0.001 30 59.72 18.09 <0.001
St III-IV 23 23.694 19.850 <0.001 28 102.44 28.22 <0.001
G1 9 1.440 0.501 <0.001 16 39.08 10.92 0.005
G2 34 16.327 13.550 <0.001 35 102.56 26.24 <0.001
G3 11 2.505 1.540 <0.001 7 63.58 22.45 0.010
Total 74 3.301 0.885 <0.001 74 70.98 14.06 <0.001
Control 64 0.037 0.012 71 12.45 3.29
* Statistical comparison (Mann-Whitney U-test) of indicated groups of patient and control samples. There were
no significant differences either in IL6 mRNA or IL6 protein expression between different subgroups of patients
according to tumor stages and grades.
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Figure 1. Salivary IL-6 mRNA and IL-6 protein expression. Expression of normalized salivary IL-6
mRNA (A) and s livary IL-6 protein (B) in a ie ts with OSCC and controls. The horizontal lines
indicate the mean. The p values are derived from the Mann-Whitney U test. Differences between Tumor
and Control groups proved significant at p < 0.001 for both salivary IL-6 mRNA normalized values and
for salivary IL-6 protein concentrations (p < 0.05 was considered significant). Dotted lines indicate the
limit of quantification (LOQ). Receiver operating characteristic (ROC) curves for diagnostic ability of
IL-6 mRNA (C) and protein (D) levels in saliva for OSCC. AUC for IL-6 mRNA = 0.9379 (p < 0.001;
95% confidence interval: 0.8973–0.9795; sensitivity: 0.945; specificity: 0.819); AUC for IL-6 protein =
0.6981 (p < 0.0001; 95% confidence interval: 0.6105–0.7858; sensitivity: 0.622; specificity: 0.789).
IL-6 protein concentration was measured in 74 suitable salivary samples of 95 patients and in 71/80
controls. Patients with OSCC, both the total p tient group d subgroups of patients according to stages and
grades, had st tistically significantly higher IL-6 concentrations than controls (Table 2, Figure 1B). There were
no significant differences in IL-6 protein concentratio s of subgroups of patients with different stages and
grades. There was a partial overlap between the distribution of the salivary IL-6 protein concentration of
the patient and the control groups (Figure 1B). Using ROC analysis, salivary IL-6 protein concentration
successfully identified patients with OSCC. The AUC for IL-6 protein was 0.6981 (p < 0.0001; 95% confidence
interval: 0.6105–0.7858; sensitivity: 0.622; specificity: 0.789) (Figure 1D).
According to the multivariate linear regression analysis, the age and DMFT score had significant
associations with ln transformed IL-6 mRNA expression levels. Sex, GI scores, alcohol consumption,
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and smoking exhibited no statistically significant association either with salivary IL-6 RNA or IL-6
protein expression (Table 3).
Table 3. Associations between demographic variables, gingival inflammation status, ethanol
consumption, and smoking habits and ln-transformed salivary levels of IL-6 mRNA and IL-6 protein
according to multivariate linear regression analysis.
In Transformed IL-6 mRNA In Transformed IL-6 Protein
Adjusted linear
regression
coefficient
p-value
Adjusted linear
regression
coefficient
p-value
Sex female/male −0.181 0.1 −0.159 0.11
Age Year 0.234 0.037 0.174 0.094
DMFT 0.234 0.037 0.174 0.094
Gingival index 0.094 0.488 0.201 0.1
Alcohol consumption
at least once a
week/less than 0.561 0.07 −0.1 0.375
once a week
Smoking
regular smoking
non-smoker or −0.134 0.232 0.005 0.959Occasional
smoker
Significant associations are indicated in bold characters.
3.3. IL-6 Protein Expression in OSCC Tumor Tissue
We performed an IHC investigation of the neoplastic lesions so as to see if the IL-6 mRNA and
protein detected in the saliva of patients with OSCC might be produced by cells in the tumor tissue.
We detected a positive IL-6 reaction in 28/41 (68%) samples. In 16/41 samples, neoplastic cells were
stained positively, and in 26/41 samples, there were detectable IL-6 protein expression in TILs (Figure 2).
TILs consisted mostly of neutrophil granulocytes, CD163-positive macrophages, and CD3-positive
T-lymphocytes. Occasionally, CD20-positive B-lymphocytes, plasma cells, and eosinophil granulocytes
were found. CD4-positive T-cells predominated over CD8-positive T-cells. The CD4:CD8 ratio was 2:1
in 30/41 (73%) of cases. We noted a CD4:CD8 inversion (CD4:CD8 < 1:2) in 5/41 (12%) cases without
signs of tumor cell destruction.
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staining). (B) A region of a representative tumor sample showing many IL-6-positive TILs, whereas 265 
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Figure 2. IL-6 protein expression in OSCC tumor tissue. Images from a representative tissue sample
exhibiting OSCC with moderate differentiation grade (G2). (A) Abundant peri- and intratumoral
tumor-infiltrating leukocytes (TILs) surrounding and intermixed with tumor cells (hematoxylin-eosin
staining). (B) A region of a representative tumor sample showing many IL-6-positive TILs, whereas cancer
cells are negative for IL-6 staining. (C) Another region of the same representative tumor sample with large
squamous carcinoma cells exhibiting IL-6 positivity. Original magnification for all three images is 20×.
Horizontal bars indicate 20 µm. Images (B) and (C) represent the immunohistochemistry (IHC) reaction
using the peroxidase-based technique with VIP chromogen, as described in Materials and Methods.
4. Discussion
The aim of the present investigation was to validate salivary IL-6 mRNA and protein as a
diagnostic biomarker of OSCC. Saliva samples from patients with histologically proven, newly
diagnosed OSCC were collected from tertiary treatment centers representing each geographic region of
Hungary. The age distribution of patients was similar to previously reported Hungarian regional and
nation-wide epidemiologic data. The predominance of female patients with 37% and the prevalence of
advanced patients (stage 3 and 4: 62%) in the present investigation was more expressed than observed
previously [1,12,20,21]. Although the distribution pattern of histological differentiation grades (G2 >
G1 > G3) was similar as that reported in a previous North-Eastern Hungarian cohort, the ratio of less
differentiated grades (G2 and G3) was slightly higher but the same as in the preliminary institutional
pilot investigation [12,20].
Salivary IL-6 was chosen as the potentially best-performing biomarker from 9 mRNA and 14
protein molecules tested in a small-scale pilot cohort of patients from one of the participating centers
(Debrecen) [12,13]. Results on quantitatively determined salivary IL-6 mRNA transcripts have not yet
been published prior to our previous pilot cohort and the present multi-center study investigating the
largest number of patients with OSCC. Earlier only one study reported on the expression of salivary
IL-6 mRNA in patients with OSCC; however, the level of expression was not quantified [22]. We found
IL-6 mRNA transcripts by qPCR in 71 of 74 saliva samples of patients with OSCC. In contrast, only
18 of 64 control saliva samples contained quantifiable levels of IL-6 mRNA transcripts, and there
was a statistically significant difference in the expression levels of normalized IL-6 mRNA transcripts
between patients and controls. With an AUC value of 0.9379 of the ROC curve, IL-6 mRNA is one of
the best-performing salivary OSCC biomarkers reported so far [10,23–25].
At the protein level, salivary IL-6 was reported most consistently to distinguish between patients
with OSCC and controls with different geographic and ethnic backgrounds. Results with other
salivary protein biomarkers were found less coherent [11]. We observed significantly higher IL-6
protein concentrations in the saliva of patients with OSCC vs. controls; however, there was a partial
overlap between the distribution of salivary IL-6 concentrations of patients and controls, resulting in
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a less favorable AUC value of the ROC curve than with salivary IL-6 mRNA. Similar salivary IL-6
concentrations to our results were observed in patients with OSCC by other investigators [4,26–35].
The attempt at normalizing salivary IL-6 protein concentration for salivary total protein concentration
abolished the significant difference of salivary IL-6 manifestation observed between patients and
controls (data not shown). IL-6 is a low-abundance salivary protein with a concentration in the pg/mL
range, whereas salivary total protein concentration is in the mg/mL range and the low signal-to-noise
ratio might obscure differences [32]. Moreover, salivary albumin, a high-abundance salivary protein,
was reported to correlate with OSCC, similar to IL-6, which may further compromise normalized
results [35]. In addition to OSCC, salivary IL-6 protein concentration was investigated in oral
premalignant lesions (OPML). The majority of investigators found significantly increased salivary IL-6
protein concentrations in patients with OPML when compared to controls, although the concentration
was less excessively elevated in OPML than in OSCC samples [26,34,36,37]. In contrast, Brailo et
al. found significantly elevated IL-6 protein concentrations in salivary samples from patients with
OSCC but not with OPML [31], suggesting that further studies are requested before establishing a
discriminatory role of salivary IL-6 protein between OSCC and OPML. Since data on salivary IL-6
mRNA in patients with OPML are lacking, we can either confirm or refute if salivary IL-6 mRNA,
although remarkably sensitive for OSCC, would be proven specific for OSCC as compared to OPML.
Few groups investigated salivary IL-6 expression in association with various tumor stages and
differentiation grades. In our study, differences both in salivary IL-6 mRNA and protein expression
levels remained significant when comparing subgroups of patients with OSCC according to the stage
and grade of their disease with controls, and there were no differences between distinct subgroups of
patients. Similar results were reported by Sato et al. and Lisa Cheng et al. [29,32]. Three other groups
observed higher salivary IL-6 concentration in patients with advanced lesions [27,32,33].
Conflicting results were reported on the potential influence of age, sex, smoking, and ethanol
consumption habits on salivary IL-6 protein concentration in patients with OSCC [27,29,31,33,36].
Using linear regression analysis, we found significant associations between age and DMFT scores and
salivary IL-6 mRNA expression confirming the results of our previous pilot studies, suggesting the
influence of oral health on salivary OSCC biomarkers [12,13]. Yet, the separation between salivary
mRNA levels of patients with and without OSCC is robust enough to maintain its value as an OSCC
biomarker. Sex, smoking, and ethanol consumption did not bias the expression of either salivary IL-6
mRNA or IL-6 protein.
In a search for the source of elevated salivary IL-6 levels in patients with OSCC, we investigated
the expression of IL-6 protein in the tumor tissue. In the majority of cases, tumor cells, and TILs were
positive for IL-6 staining. Similar observations were reported in one publication [38]. These results,
together with experimental evidence, suggest that a paracrine loop of stimulation may exist between
neoplastic and nonmalignant cells of the tumor microenvironment [39,40]. The positive feedback loop
of stimulation may explain the significant upregulation of salivary IL6 expression in patients with
OSCC both at the mRNA and protein level when compared to controls. Thus, the IL-6-IL-6 receptor
interaction may offer therapeutic targets in OSCC [41].
In conclusion, salivary IL-6 mRNA is a robust biomarker for OSCC in the Hungarian population
in comparison with tumor-free control persons. However, caution is warranted before claiming the
specificity of this biomarker without investigating salivary IL-6 mRNA in patients with OPML. Further
investigations, involving patients from different ethnic groups and geographic regions may prove the
value of quantitative salivary IL-6 mRNA expression as a general OSCC biomarker. The relevance
of salivary IL-6 mRNA in OSCC was supported by the significantly elevated salivary IL-6 protein
concentration in patients with OSCC vs. controls. Moreover, intratumor IL-6 production both by tumor
cells and TILs, detected by IHC, may serve as a likely source of salivary IL-6 mRNA and protein in
patients with OSCC.
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